A 51-year-old woman with Crohn's disease who is taking infliximab (Remicade) calls the nurse in the outpatient clinic about new symptoms. Which symptom is most important to communicate to the health care provider?

Choice A reason: Joint pain (arthralgia) is a common extraintestinal manifestation of Crohn's disease and can also be a side effect of biologic therapy. While uncomfortable and worth noting, it is not typically an acute life-threatening emergency. It does not carry the same immediate clinical urgency as a sign of systemic infection in an immunocompromised patient. Choice B reason: Infliximab is a tumor necrosis factor (TNF) inhibitor that significantly suppresses the immune system. Patients taking biologics are at high risk for serious opportunistic infections, including tuberculosis and sepsis. A fever may be the only early sign of a life-threatening infection, requiring immediate cessation of the drug and medical evaluation. Choice C reason: Headache is a frequently reported side effect of infliximab infusions. While it should be monitored, it is generally considered a minor adverse effect unless it is exceptionally severe or accompanied by neurological deficits. It does not indicate the high level of physiological risk that a fever does in an immunosuppressed individual. Choice D reason: Nausea is another common side effect associated with many medications, including biologics for inflammatory bowel disease. While it affects the client's quality of life and nutritional status, it is not an indicator of an acute, high-priority safety concern like a potential systemic infection or a severe hypersensitivity reaction.